t
On 22 October 2026, TheraCryf plc held its Annual General Meeting. The company announced that all resolutions presented at the meeting were duly passed by shareholders. Full voting results from the AGM have been made available on the company's website.
| Date | 22 Oct 2026 |
| Time | 14:44:32 |
| Category | AGMs and other meetings |
| ID | 1074A |
22 October 2026
TheraCryf plc
("TheraCryf", the "Company" or the "Group")
Result of Annual General Meeting
TheraCryf plc, the biotech company developing new medicines for addiction and other neuropsychiatric disorders, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
The AGM voting results will be available on the Company's website here.
-Ends-
Enquiries
|
TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, COO
|
+44 (0)1625 315 090 |
|
Strand Hanson (Financial & Nominated Adviser)
|
+44 (0)20 7409 3494 |
|
Turner Pope Investments (Broker) Andy Thacker / Guy McDougall
|
+44 (0)20 3657 0050
|
|
Northstar Communications (Investor Relations) Sarah Hollins |
+44 (0)113 730 3896
|
About TheraCryf
TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need.
The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders.
The programme has already been heavily de-risked for both safety/tolerability and efficacy in previous testing and is fully funded through final pre-clinical trials to clinical readiness, with regulatory submissions for first in man studies targeted for 2026.
TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.
The Group operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with commercially focused pharmaceutical and biotechnology companies.
TheraCryf’s headquarters and registered office are at Alderley Park, Cheshire.
For further information, visit: https://theracryf.com